Day: November 5, 2024

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 04 11 2024] – (CGWL)

Written by Customer Service on November 5, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Form 8.3 – [ECKOH PLC – 04 11 2024] – (CGWL)

Written by Customer Service on November 5, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ECKOH PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Eimskip: Third quarter 2024 results

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Highlights of Q3 2024 results Good revenue growth resulting in the best quarter this year and close to a good third quarter last year. Revenue increased by EUR 18.6m from last year and amounted to EUR 220.6m in the quarterLiner revenue decreased by EUR 2.7m while Forwarding revenue increased by EUR 21.3m Liner revenue in the quarter were the strongest this yearGood growth in export from Iceland and high activity in domestic Iceland as well as increased volume in Trans-Atlantic combined with higher ratesIncrease in Forwarding revenue driven by higher global freight rates especially in Asia connected trade lanesExpenses amounted to EUR 187.7m, an increase of EUR 20.2m, driven by cost of third-party logistics services which increased by EUR 17.8m from previous yearBunker expenses decreased by EUR 0.2m despite the cost of the...

CORRECTION – Willis Lease Finance Corporation Reports Strong Third Quarter Pre-Tax Income of $34.5 million; Pre-Tax Income Up 69% as Compared to that of the Third Quarter of the Prior Period; Board Declares Recurring Quarterly Dividend of $0.25 Per Share of Common Stock

Written by Customer Service on November 5, 2024. Posted in Dividend Reports And Estimates.

COCONUT CREEK, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline by Willis Lease Finance Corporation, the $48.5 million of short-term maintenance revenues earned was reported as the total year-to-date amount earned during the first three quarters of 2024, but this has been corrected to reflect that this amount was earned during the third quarter of 2024. The corrected release follows: Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”) today reported third quarter total revenues of $146.2 million and quarterly pre-tax income of $34.5 million. The Company also announced its quarterly dividend of $0.25 per share, expected to be paid on November 21, 2024, with a record holder date of November 12, 2024. For the three months ended September 30, 2024, core lease rent and maintenance...

Seanergy Maritime Reports Third Quarter and Nine Months Financial Results for the Periods Ended September 30, 2024

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

Declares Cash Dividend of $0.26 Per Share Reflecting Strong Financial ResultsHighlights (in million USD, except EPS) Q3 2024 Q3 2023 9M 2024 9M 2023Net Revenues $44.4 $24.5 $125.8 $70.8 Net income / (loss) $12.5 ($5.0) $36.8 ($8.5) Adjusted net income / (loss)1 $14.1 ($2.6) $41.7 $0.4 EBITDA1 $25.2 $7.1 $72.7 $27.9 Adjusted EBITDA1 $26.8 $9.5 $78.0 $29.1 Earnings / (loss) per share Basic $0.61 ($0.28) $1.80 ($0.48) Earnings / (loss) per share Diluted $0.61 ($0.28) $1.79 ($0.48) Adjusted earnings / (loss) per share Basic1 $0.69 ($0.14) $2.05 $0.02 Adjusted earnings / (loss) per share Diluted1 $0.69 ($0.14) $2.04 $0.02 Other Highlights and Developments:Record Nine-Month Net Income of $36.8 million Quarterly cash dividend of $0.26...

UFP Technologies Announces Record Q3 2024 Results

Written by Customer Service on November 5, 2024. Posted in Earnings Releases And Operating Results.

NEWBURYPORT, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — UFP Technologies, Inc. (Nasdaq: UFPT), an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported that net income increased 40% to $16.4 million in the third quarter of 2024 from $11.7 million in the third quarter of 2023. Sales for the third quarter increased 44% to $145.2 million compared to 2023 third quarter sales of $100.8 million. Net income increased 28% to $42.6 million for the nine-month period ended September 30, 2024 from $33.3 million in the same period of 2023. Sales for the nine-month period ended September 30, 2024 increased 21% to $360.4 million compared to sales of $298.6 million in the same period in 2023. Throughout this news release, reference...

Crown Announces Suspension of Equity Line of Credit

Written by Customer Service on November 5, 2024. Posted in Public Companies.

LOS ANGELES, Nov. 05, 2024 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading provider of cutting edge technology solutions that benefit communities and the environment, today announced that it has suspended the use of its Equity Line of Credit (ELOC) agreement with Liqueous LP. “Recently, Crown had an initial, modest use of the ELOC, but has now made the decision to suspend its use. We established the ELOC to complement our existing capital options and provide flexibility to cover any funding gaps. However, at this time, we no longer deem it necessary to support our current financing strategy and strengthened outlook,” stated Doug Croxall, CEO and Chairman, Crown. “At Crown, we are dedicated to protecting shareholder value and have consulted with professionals...

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Written by Customer Service on November 5, 2024. Posted in Public Companies.

MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. Ladenburg Thalmann...

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Written by Customer Service on November 5, 2024. Posted in Public Companies.

Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline. Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process. 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (Nasdaq: MSFT), the world’s leading AI company. Using Microsoft’s suite of advanced tools, Tevogen Bio is...

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

Written by Customer Service on November 5, 2024. Posted in Public Companies.

– CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy – – First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain – – Data demonstrated sustained anti-tumor activity and a lack of functional exhaustion during repeated challenge from tumor cells, preservation of T cell memory phenotype relative to controls, sustained tumor clearance when only a single antigen is expressed, and robust in vivo, anti-lymphoma activity at low CAR T dose levels – – Abstract will be presented...

Day: November 5, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals